Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

• Status: Completed
• Trial end date: 2018-08-22
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this study are to investigate the safety and effectiveness of EYLEA.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Collaborator: Regeneron Pharmaceuticals
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• Patients who start EYLEA treatment for mCNV(myopic choroidal neovascularization).

Exclusion Criteria:

• Patients who have already received EYLEA treatment.